Neos Therapeutics Announces Positive Phase 3 Study Results For Its Methylphenidate Extended-Release (XR) Oral Disintegrating Tablet (ODT) In ADHD Patients

Published: Jul 15, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

GRAND PRAIRIE, Texas--(BUSINESS WIRE)--Neos Therapeutics, Inc. (“Neos” or “the Company”), a highly differentiated oral drug delivery company with a portfolio of proprietary technologies and a late-stage pipeline of innovative controlled release (CR) products for ADHD, announced today that it has completed a positive Phase 3 study for its methylphenidate XR-ODT drug candidate, NT-0102, in children with ADHD.

Help employers find you! Check out all the jobs and post your resume.

Back to news